Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1652576 | 0.88 | PTPN1 (0.33) | ALDH1A1PTPN1ESR1ESR2MAT2A | |
| SCHEMBL1652581 | 0.88 | PTPN1 (0.33) | ALDH1A1PTPN1ESR1ESR2MAT2A | |
| SCHEMBL12777823 | 0.85 | ESR1 (0.33) | MAPTNPSR1ALDH1A1PTPN1SMN1; SMN2 | |
| SCHEMBL1652584 | 0.82 | ESR1 (0.30) | PTPN1ESR1ESR2 | |
| SCHEMBL11899808 | 0.81 | RORC (0.34) | MAPTALDH1A1POLBPTPN1RORC | |
| SCHEMBL1651855 | 0.80 | BRD4 (0.43) | — | |
| SCHEMBL1651727 | 0.80 | NPC1 (0.32) | MAPTALDH1A1NPC1RAB9AESR1 | |
| SCHEMBL11898999 | 0.77 | POLB (0.35) | MAPTGAANPSR1ALDH1A1POLB | |
| SCHEMBL19471990 | 0.75 | POLB (0.33) | MAPTALDH1A1POLBPTPN1RORC | |
| SCHEMBL1652989 | 0.75 | PTPN1 (0.37) | MAPTGAAALDH1A1POLBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486010-B1 | ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-06-12 | — | — | EP | claimed |
| CN-102791688-B | Estrogen receptor ligands | KAROBIO AB | 2014-11-12 | — | — | CN | claimed |
| US-8710243-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-04-29 | — | — | US | claimed |
| EP-2486010-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-15 | — | — | EP | claimed |
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-09 | — | — | US | claimed |
| WO-2011042473-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-04-14 | — | — | WO | claimed |
| EP-3782616-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3782616-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | The Regents of The University of California (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3189026-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-2486010-B1 | ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-06-12 | — | — | EP | disclosed |
| US-8710243-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| EP-2486010-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011042473-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042473-A2 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | MAPT 289/4885GAA 3262/4885NPSR1 133/4885 |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | MAPT 289/4885GAA 3262/4885NPSR1 133/4885 |
| US-20120202861-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | MAPT 3766/4885GAA 3969/4885NPSR1 57/4885 |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | MAPT 289/4885GAA 3262/4885NPSR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.